Company
Aptacure Therapeutics Limited (Aptacure) is a biotechnology company based in Hong Kong Science Park. The core technology is originated from more than ten years research in Professor Zhang Ge’s group in Hong Kong Baptist University. The company is aim to develop aptamer-based innovative drugs to treat bone disease and other unmet medical need.
For the leading program Apc001, it is targeted sclerostin to increase the bone anabolic effect. The potential indication includes osteogenesis imperfecta, osteoporosis, fracture healing, etc. Apc001 has been granted Orphan Drug Designation for treating osteogenesis imperfecta by US FDA in 2019. The second program Apc002, is developed for treating bone metastasis, gastric cancer and esophagus cancer, it is in discovery phase.
